DYVE BIOSCIENCES
Dyve creates novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery. The company is rapidly developing a strong pipeline across a broad range of therapeutic areas based around its proprietary science. Dyve’s most advanced asset, DYV-700, is in phase 2 for the treatment of acute gout using a mechanism of action enabled by Dyve’s science. The company has PK data demonstrating injection-like delivery across a broad range of molecules. It was founded in 2014 and is headquartered in Thousand Oaks, California.
DYVE BIOSCIENCES
Social Links:
Industry:
Biopharma Biotechnology
Founded:
2014-11-01
Address:
Thousand Oaks, California, United States
Country:
United States
Website Url:
http://www.dyvebio.com
Total Employee:
11+
Status:
Active
Contact:
805-857-6449
Email Addresses:
[email protected]
Total Funding:
9.76 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Imara
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Navitor Pharmaceuticals
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
NGM Biopharmaceuticals
NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.
Rainier Therapeutics
Rainier Therapeutics is a developer of cancer therapeutics technology intended to offer advanced targeted therapy for bladder cancer.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
NaHCO3
NaHCO3 investment in Funding Round - Dyve Biosciences
Official Site Inspections
http://www.dyvebio.com
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Dyve Biosciences"
Dyve Biosciences - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 805-857-6449 Dyve creates novel therapeutics using proprietary science that leverages the skin as a portal for systemic delivery.See details»
Dyve Biosciences - LinkedIn
At Dyve Biosciences, we leverage our proprietary transdermal platform to deliver intuitive, targeted pH modulation to treat a range of immunologic and oncologic diseases.See details»
Dyve Biosciences Company Profile | Management and Employees …
[email protected]: Dyve Biosciences Top Competitors. Company Employees Revenue Top technologies; CinRx. 20: $4 M: Melior Discovery Inc. 32: $11.1 M: Bionavigen. 5: $917 K: …See details»
Dyve Biosciences - Overview, News & Similar companies - ZoomInfo
Apr 11, 2023 View Dyve Biosciences (www.dyvebio.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees …See details»
Dyve Biosciences to Participate in the BIO International
Jun 1, 2022 BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. ...See details»
Dyve Biosciences - Org Chart, Teams, Culture & Jobs | The Org
Dyve is a clinical-stage biotech company with its lead asset, DYV700, currently completing a 20-center, 100-patient, Phase 2 clinical study for the treatment of acute gout.See details»
Dyve Biosciences - VentureRadar
"Dyve Biosciences created a breakthrough platform technology that broadly enables transdermal drug delivery. Dyve has advanced clinical programs in gout and melasma that demonstrate the …See details»
Dyve Biosciences, Inc. - Drug pipelines, Patents, Clinical trials
Www.dyvebio.com. Startups | Private Company | 2014 | California, United States | 10-50 | www.dyvebio.com. Last update 23 Jan 2025. Overview. Pipeline. Deal. Translational …See details»
Dyve Biosciences to Participate in the BIO International Convention
CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal ...See details»
Dyve Biosciences - PitchBook
Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; US-20240424016-A1: Buffering for non-alcoholic steatohepatitis and liver diseasesSee details»
Dyve Biosciences Appoints Tatyana Beldock to Board of Directors
Apr 11, 2023 Learn more at www.dyvebio.com. Contacts. Corporate & Investor Contact Jim McGee Dyve Biosciences, Inc. 833-398-3246 [email protected]. Release Summary.See details»
Dyve Biosciences to Participate in the BIO International Convention
CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a …See details»
Press Release | Dyve Biosciences
CAMARILLO, Calif., June 01, 2022 (GLOBE NEWSWIRE) — Dyve Biosciences, Inc. (“Dyve”), a clinical-stage biotech company applying its proprietary transdermal delivery technology to a …See details»
Dyve Biosciences - Work in biotech
Dyve Biosciences is developing technology that can utilize the skin as a delivery modality to treat immunologic and oncologic diseases. During tumorigenesis the microenvironment often …See details»
Ryan Beal, M.D. CEO Dyve Biosciences - attendais.com
DYV-600: Overview of Melasma Clinical Programs • DYV-601: Feasibility Open label feasibility in treatment resistant patients. • DYV-602: Split–face Versus 4% Hydroquinone (HQ) …See details»
Dyve Biosciences Presents Preclinical Data from Lead Oncology …
CAMARILLO, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. (“Dyve”), a clinical-stage platform biotechnology company with assets in immunology and oncology, today announced the …See details»
Dyve Biosciences Announces Chuck Harbert, Ph.D. to Join as Chief ...
THOUSAND OAKS, Calif.–(BUSINESS WIRE)–Dyve Biosciences, Inc. today announced that longtime Pfizer Executive Chuck Harbert, Ph.D. has joined the company in the role of Chief …See details»
HiveBio selects 10 startups for first life sciences accelerator ...
4 days ago Here are the members of HiveBio's first cohort for its life sciences accelerator program geared towards underrepresented entrepreneurs.See details»
Dyve Biosciences Announces the Appointment of Nicholas A.
Dyve’s novel technology platform carries a robust portfolio of both pending and issued patents. For more information, please visit www.dyvebio.com. Corporate Contact Jim McGee Dyve …See details»
Dyve Biosciences Announces Research and Development …
For example, Dyve’s lead asset, pH-modulator DYV702, recently completed a successful multi-center, 100-patient, Phase 2 clinical study for reducing the pain associated with acute gouty …See details»